drugset / Trial / NCT00791219

Study Comparing SUBA™-Itraconazole With SPORANOX® (Itraconazole) in the Treatment of Onychomycosis

NCT00791219

Phase 2 Completed 175 enrolled Halcygen Pharmaceuticals Limited
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to compare the relative efficacy and safety of SUBA™-Itraconazole Capsules (HalcyGen Ltd) to an already marketed oral formulation of itraconazole SPORANOX® (itraconazole) capsules (Janssen Pharma) in the treatment of onychomycosis of the toenail. Both the test and the reference formulations will also be compared to a placebo formulation to test for superiority.

Timeline

Start
2008-11
Primary completion
2010-07
Completion
2010-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Itraconazole Small molecule 100 mg Oral
Subject Itraconazole Small molecule 200 mg Oral

Indications